Diagnosed Mild Cognitive Impairment Due to Alzheimer's Disease with PET Biomarkers of Beta Amyloid and Neuronal Dysfunction

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Hatashita, Shizuo ^a   Yamasaki, Hidetomo ^a  

^a Shonan Atsugi Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; EPISODIC MEMORY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; MOLECULAR IMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRECUNEUS; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BIOLOGICAL MARKERS; CEREBRAL CORTEX; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; THIAZOLES;

EID: 84879036616     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066877     Document Type: Article

References (20)

1. Petersen RC, Aise PS, Beckett LA, Donohue MC, Gamst AC, et al. (2010) Alzheimer's Disease Neuroimaging Initiative (ADNI). Neurology 74: 201-209.
2. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateauet P, et al. (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6: 734-746.
3. Albert MS, DeKosky ST, Diskson D, Dubois B, Feldman HH, et al. (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendation from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 270-279.
4. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, et al. (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29: 1456-1465.
5. Jack CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, et al. (2009) Serial PIB and MCI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathologic events in Alzheimer's disease. Brain 132: 1355-1365.
6. Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, et al. (2010) Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75: 230-238.
7. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, et al. (2003) Synthesis and evaluation of [11C]-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46: 2740-2754.
8. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, et al. (2004) Imaging brain amyloid in Alzheimer' disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319.
9. Hatashita S, Yamasaki H, (2010) Clinically different stages of Alzheimer's disease associated by amyloid deposition with [11C]-PIB PET imaging. J Alzheimers Dis 21: 995-1003.
10. Folstein MF, Folstein SE, McHugh PR, (1975) 'Mini-mental state' A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
11. Morris JC, (1993) The clinical dementia rating (CDR): current version and scoring rules. Neurology 43: 2412-2414.
12. Wechsler DA, et al. (1987) Wechsler Memory Scale-Revised. New YorkPsychological Corporation. New York.
13. Mckhann G, Drachman DA, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease-report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34: 939-944.
14. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, et al. (2005) Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 46: 1959-1972.
15. Okello A, Koivumen J, Edison P, Acher HA, Turkheimer FE, et al. (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: An [11C]-PIB PET study. Neurology 73: 754-760.
16. Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, et al. (2011) Longitudinal Assessment of AB and cognition in Aging and Alzheimer Disease. Ann Neurol 69: 181-192.
17. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Wiiloch F, et al. (2003) Cerebral metabolic change accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 30: 1140-1113.
18. Drzezga A, Grimer T, Riemenschneider M, Lautenschlager N, Siebner H, et al. (2005) Prediction of individual clinical outcome in MCI by means of genetic assessment and [18F]-FDG PET. J Nucl Med 46: 1625-1632.
19. Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Peterson RC, et al. (2012) Prediction of conversion from mil cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging 33: 1203-1214.
20. Zhang S, Han D, Tan X, Feng J, Guo Y, et al. (2012) Diagostic accuracy of [18F]-FDG and [11C]-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment. Int J Clin Pract 66: 185-198.